Table 1 Clinicopathological characteristics before surgery (n = 13)
Age (y.o.) | 66.4 (52–83) |
Gender | Male: Female 8: 5 |
Brinkmann index | 704.8 (0–1560) |
Location | |
Right upper lobe | 7 |
Right middle lobe | 0 |
Right lower lobe | 3 |
Left upper lobe | 2 |
Left lower lobe | 1 |
Maximum tumor diameter (mm) | 56.5 (14–96) |
Histology | |
Adenocarcinoma | 10 |
Squamous cell carcinoma | 1 |
Large cell neuroendocrine carcinoma (LCNEC) | 2 |
c-stage | |
c-stage IIIA | 1 |
c-stage IIIB | 5 |
c-stage IVA | 5 |
c-stage IVB | 2 |
Metastasis | Total number |
Abdominal lymph nodes | 1 |
Pleural dissemination | 1 |
Lung | 4 |
Bone | 1 |
Brain | 2 |
Driver mutation | |
Negative | 10 |
BRAF V600E | 1 |
Not examined | 2 |
Tumor proportion score (TPS) | |
< 1% | 0 |
1% ≤ < 50% | 6 |
50% ≤ | 7 |
Preoperative chemotherapy | |
Platinum, pemetrexed and pembrolizumab | 6 |
Pembrolizumab | 4 |
Platinum, VP16, and Atezolizumab | 1 |
Platinum, pemetrexed, nivolumab, and ipilimumab | 1 |
Nivolumab and ipilimumab | 1 |
Tumor diameter before surgery (mm) | 36.5 (8–110) |
SUVmax before surgery | 6.15 (0–12.7) |
yc-stage | |
yc-stage IA | 3 |
yc-stage IB | 3 |
yc-stage IIA | 1 |
yc-stage IIB | 1 |
yc-stage IIIA | 4 |
yc-stage IVA | 1 |
Time from initial treatment to surgery (months) | 10.1 (2–40) |